References
1. Weda M, Hoebert J, Vervloet M, et al. Study on off-label use of medicinal products in the European Union. European Union2017.
2. Commission E. State of Paediatric Medicines in the EU 10 years of the EUPaediatric Regulation. https://ec.europa.eu/health/system/files/2017-11/2017_childrensmedicines_report_en_0.pdf. Published 2017. Accessed March 8, 2022.
3. conect4children. Collaborative Netwerk for European Clinical Trials for Children. www.conect4children.org.Accessed March 8, 2022.
4. Smits A, Annaert P, Cavallaro G, et al. Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British journal of clinical pharmacology. 2021.
5. Aurich B, Apele-Freimane D, Banaschewski T, et al. c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper.British journal of clinical pharmacology. 2021.
6. Walsh J, Schaufelberger D, Iurian S, et al. Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper. British journal of clinical pharmacology. 2021.
7. Moretti F, Ruiz F, Bonifazi F, Pizzo E, Kindblom JM. Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project.British journal of clinical pharmacology. 2021.